ESC 24: Hot Line & Late-breaking Science Video Collection
Published: 15 August 2024
-
Views:
2589 -
Likes:
7
-
Views:
2589 -
Likes:
7
-
4m 54sPart 5 | Session 1 3 Trials That Will Change My Practice With Dr Muthiah Vaduganathan
-
13m 47sPart 5 | Session 2 3 Trials That Will Change My Practice With Dr Michelle Kittleson
-
6m 55sPart 6 | Session 1 New Guidelines for the Management of Atrial Fibrillation
-
6m 13sPart 6 | Session 2 New Guidelines for the Management of Aortic Diseases
-
47m 31sPart 1 | Session 1 ESC Congress 2024 Hot Line Wrap Up Nicolas M Van Mieghem, Joost Daemen
-
27m 27sPart 1 | Session 2 ESC Congress 2024 Hot Line Preview Nicolas M Van Mieghem, Joost Daemen
-
17m 25sPart 2 | Session 1 ESC Day 1 Wrap Up: New Guidelines, HELIOS-B, ABYSS & STOP-or-NOT Mirvat Alasnag, Khaled Al-Shaibi
-
23m 2sPart 2 | Session 2 ESC Day 2 Wrap-Up: NOTION-3, RESHAPE-HF2, TRI.Fr & More Mirvat Alasnag, Khaled Al-Shaibi
-
12m 28sPart 2 | Session 3 Day 3 Wrap-Up with Dr Alasnag and Dr Al-Shaibi Mirvat Alasnag, Khaled Al-Shaibi
-
15m 45sPart 2 | Session 4 Day 4 Wrap-Up: OCCUPI, REC-CAGEFREE I, AEGIS-II & More Mirvat Alasnag, Khaled Al-Shaibi
-
20m 58sPart 3 | Session 1 AβYSS: Beta Blocker Interruption After Uncomplicated MI Harriette Van Spall, Prof. Johanne Silvain
-
20m 14sPart 3 | Session 2 RHEIA: TAVR vs SAVR in Women with Severe AS Helene Eltchaninoff, Harriette Van Spall
-
8m 47sPart 3 | Session 3 OCEANIC-AF: Asundexian Vs Apixaban in Atrial Fibrillation Manesh R Patel, Harriette Van Spall
-
9m 29sPart 3 | Session 4 SWEDEGRAFT: No-touch Vein Graft in CABG Harriette Van Spall, Stefan James
-
17m 28sPart 3 | Session 5 FINEARTS-HF: Finerenone HFmEF & HFpEF Harriette Van Spall, Scott Solomon
-
6m 8sPart 4 | Session 1 Bridging the Gap in Heart Failure Guideline Implementation from a Specialist Nurse Perspective Carys Barton
-
5m 29sPart 4 | Session 2 MATTERHORN: M-TEER vs Surgery in Heart Failure Volker Rudolph, Stephan Baldus
-
5m 46sPart 4 | Session 3 MRAs in Heart Failure Pardeep Jhund
-
4m 24sPart 4 | Session 4 FINE-HEART: Finerenone in HF & CKD Muthiah Vaduganathan
-
8m 18sPart 4 | Session 5 STEEER-AF: Stroke Prevention & Rhythm Control Therapy Dipak Kotecha
-
3m 52sPart 4 | Session 6 NOTION-3: FFR Guided PCI in TAVI Jacob Thomsen Lønborg
-
6m 48sPart 4 | Session 7 EPIC-CAD: Edoxaban vs Dual Antiplatelet Therapy in AF & CAD Gi-Byoung Nam, Min Soo Cho
-
8m 17sPart 4 | Session 8 SENIOR RITA: Invasive Vs Conservative Strategy for Older Patients with MI Vijay Kunadian
-
3m 51sPart 4 | Session 9 EARTH-STEMI: Complete Vs Culprit-Only Revascularization in Older Patients Gianluca Campo
-
4m 17sPart 4 | Session 10 SCOFF: Fasting vs. Non-Fasting: Impact on Cardiac Catheterization Outcomes David Ferreira
-
4m 17sPart 4 | Session 11 GUARD-AF: Atrial Fibrillation Screening to Reduce Stroke in Elderly Individuals Renato D Lopes
Overview
What's hot at the ESC Congress 2024?
Stay ahead of the curve with our faculty-led coverage of the European Society of Cardiology Congress in London. From groundbreaking trials to expert insights, we've got you covered.
- Watch our View From the Thoraxcenter series for practice-focused reviews of the most anticipated trials from interventional experts, Prof Nicolas Van Mieghem and Dr Joost Daemen.
- For a deeper dive into key hot line clinical trial data and its applicability, host, Dr Harriette Van Spall meets with principal investigators in her Late-Breaker Discussion series.
- View a condensed summary of the crucial takeaways from each day in our Wrap-Up series led by Dr Mirvat Alasnag.
- Our short, bite-sized Expert Interviews with select faculty will focus on data, take-home messages for practice and the future of their field.
Get ready for a deep dive into the latest cardiology research. Our coverage of the ESC Congress is coming soon.
More from this programme
Part 1
View From the Thoraxcenter: What's Hot at ESC 24?
Part 2
Daily Wrap Ups with Dr Alasnag and Dr Al-Shaibi
Part 3
Hot-line Discussions with Dr Harriette Van Spall
Part 4
Expert Interviews
Part 5
Highlights
Part 6
Guidelines
About the episode
ESC Congress 24 — SHAM-PVI study finds pulmonary vein isolation effective in reducing atrial fibrillation (AF) episodes, improving quality of life.
We are joined onsite by Dr Rick Veasey (Eastbourne District General Hospital, Eastbourne, UK) to discuss the findings from a SHAM-PVI, a randomized sham-controlled study of pulmonary vein isolation in symptomatic atrial fibrillation (NCT04272762; East Sussex Hospitals NHS Trust).
SHAM-PVI aims to evaluate the effectiveness of cryoablation in the treatment of atrial fibrillation as compared to placebo. 140 adults with symptomatic atrial fibrillation who had not responded to at least one antiarrhythmic drug (AAD Type I or III, β-blocker or AAD intolerance) were enrolled in the trial. These patients were randomized to receive either pulmonary vein isolation (PVI), or a sham procedure.
Primary outcomes include the burden of atrial fibrillation over a period of 6 months, and secondary outcomes comprise of the patient's quality of life, healthcare usage and complications.
Investigators find that PVI significantly reduced the occurrence of AF and improved symptoms and quality of life for patients. After six months, there was no significant placebo effect observed with PVI.
Interview Questions:
- What is the current research landscape for PVI treatment for AF?
- What was the study design and patient population for SHAM-PVI?
- What are your key findings?
- What are your take-home messages?
- What further research is needed, and what are the next steps?
Recorded on-site at ESC Congress 2024, London.
Editors: Jordan Rance and Mirjam Boros.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David-Ben-Harosh.
Support: This is an independent content produced by Radcliffe Cardiology.
Comments